Dental Bone Graft Substitute Market – Technological Advances in Xenograft Materials for Dental Applications

The study involved four major activities to estimate the current size of the dental bone graft substitute market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth:

[147 Pages Report] The dental bone graft substitute market size is projected to reach USD 659 million by 2025 from USD 450 million in 2020, at a CAGR of 7.9%.

Covid-19 Impact On Dental Bone Graft Substitute Market:

The dental bone graft substitute market is impacted due to the pandemic, resulting in short term negative growth due to factors such as a sharp decline in elective surgeries. Moreover, dental clinics were temporarily closed, and hospital access restricted to non-essential care. Thus, limited access to clinics, social distancing, the lockdown of the population, which results in less trauma and workplace injuries, and slow-down in patient flow and referrals has also impacted the market growth.

Download PDF Brochure:

Major Growth Dynamics of Dental Bone Graft Substitute Market:

1. Growing geriatric population
2. Growing medical and dental tourism in developing countries
3. Increasing disposable income in developing countries
4. Increasing demand from customers and rising inclination toward cosmetic dentistry
5. Growing demand for bone graft substitutes from emerging markets

Key Players Mapped I Research Report:

1. Dentsply Sirona (US)
2. Johnson & Johnson (US)
3. Danaher Corporation (US)
4. Medtronic (Ireland)
5. Strauman (US)
6. Zimmer Dental (US)
7. Geistlich Pharm (Switzerland)
8. RTI Surgical (US)
9. BioHorizons, IPH, Inc (US)
10. Dentium (South Korea)

Danaher is one of the leaders in designing, manufacturing, and marketing innovative products and services to professional, medical, industrial, and commercial customers.

Hospitals are the Largest End User of Dental Bone Graft Substitute Market:

This end-user segment includes the market for dental bone graft substitutes used in hospitals, small clinics, and critical care units. Positive demand growth of dental bone graft substitutes by hospitals are mainly attributed to the advancements in orthodontic treatment and cosmetic dentistry, growing geriatric population and increasing number of cosmetic dentistry procedures. The results of a survey conducted by the American Association of Oral and Maxillofacial Surgeons in the US were as follows:

1. Over 30 million people do not have teeth in one or both jaws
2. 26.0% people aged above 75 years do not have teeth at all
3. 69.0% of people aged between 35 and 45 years have one tooth missing
4. More than 15 million people have crowns or bridges
5. Approximately 500,000 people undergo dental implant procedure each year
6. Dental implants have a success rate of about 95.0%.

The Geographical Regions Mapped in the Report are:

1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)

Europe is one of the major revenue-generating regions in the dental bone graft substitute market. The favorable reimbursement & insurance coverage for major procedures and supportive government regulations for product commercialization are the major factors driving the growth of the dental bone graft substitute industry in Europe.

Request Sample Report:

Recent Developments in Dental Bone Graft Substitute Market:

In 2019, Straumann and Modern Dental Group Limited (Hong Kong) entered a joint venture to create distribution company that will serve the dental communities in Hong Kong and Macau; Peak Dental Solutions Hong Kong Ltd.

In 2018, Dentsply acquired OraMetrix, a leading industry provider of innovative 3-D technology solutions improving the quality and efficiency of orthodontic care.

In 2018, Straumann acquired 30% stake in Botiss biomaterials.

Leave a Reply

Your email address will not be published.